Table 4 Comparison of AEs risk between T-VEC alone and in combination with ICIs
Immune checkpoint inhibitors | Preferred term | N | ROR (95%CI) |
|---|---|---|---|
Pembrolizumab | MALIGNANT MELANOMA | 9 | 2.83 (1.32-6.05) |
MALIGNANT NEOPLASM PROGRESSION | 6 | 5.95 (2.15-16.42) | |
RASH | 6 | 3.24 (1.27-8.26) | |
DYSPNOEA | 5 | 5.40 (1.81-16.11) | |
IMMUNE-MEDIATED ADVERSE REACTION | 4 | 43.14 (4.78-389.59) | |
AUTOIMMUNE COLITIS | 4 | 21.55 (3.90-119.08) | |
PLATELET COUNT DECREASED | 4 | 8.60 (2.27-32.51) | |
HYPOTENSION | 4 | 4.28 (1.32-13.88) | |
Ipilimumab | DRUG INEFFECTIVE | 6 | 12.03 (4.51-32.12) |
MALIGNANT NEOPLASM PROGRESSION | 4 | 13.25 (4.06-43.3) | |
MALIGNANT MELANOMA | 4 | 4.21 (1.41-12.59) | |
DEATH | 4 | 3.02 (1.02-8.93) | |
Atezolizumab | CYTOKINE RELEASE SYNDROME | 4 | 56.10 (13.14-239.51) |
Nivolumab | OFF LABEL USE | 13 | 2.16 (1.12-4.15) |
DRUG INEFFECTIVE | 8 | 10.30 (4.31-24.61) | |
DEHYDRATION | 4 | 20.03 (5.21-77.08) | |
SEPSIS | 4 | 11.09 (3.29-37.35) |